TCTR20170928005尚未招募3 期
A paired, randomized, double-blind, placebo-controlled trial of EMLA cream (eutectic mixture of local anesthetics) for primary localized cutaneous amyloidosis
none0 个研究点目标入组 15 人开始时间: 2017年9月28日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 60 Years（—）
- 性别
- All
入选标准
- •18-60 years old
- •primary localized cutaneous amyloidosis at both legs
排除标准
- •1.previous laser within 3 months or use topical treatment within 1 month
- •2.other skin diseases
- •3.pregnancy or lactation
- •4.history of allergy to anesthesic agents or amide derivative
- •5.glucose-6-phosphatase defiency (G6PD)
- •6.using nitric oxide, sulfonamides, dapsone, metoclopramide, nitrofurantoin, beta-blockers drug
- •7.arrhythmia
- •8.immunodeficiency
- •9.psychiatric problem
研究者
相似试验
尚未招募
2 期
A randomized, double-blind, split-faced study comparing A.I. Clearing Treatment with 0.1% adapalene versus 0.1% adapalene in treatment of mild to moderate degree acne vulgarismild to moderate degree acne vulgarisacne vulgarisadapaleneglycolic acidsalicylic acidgluconolactonelicochalcone AmoistureA.I. Clearing TreatmentacneTCTR20171031005Beiersdorf (Thailand) Co., Ltd.25
Enrolling By Invitation
不适用
Calcitriol combined with ergocalciferol in CKD with proteinuriaDo both natural vitamin D (ergocalciferol) and active viatamin(calcitriol) decrease proteinuria in CKD stage 3 and 4 with proteinuria more than 1 gram/day?TCTR20140929002Faculty of Medicine,Chulalongkorn University140
招募中
3 期
ß-amyrin Palmitate with Activated Curcumin Complex combination versus Metformin in newly diagnosed patients of type 2 diabetes mellitus associated with dyslipidemiaCTRI/2023/09/057969Sam Sabinsa Group Limited
已完成
4 期
Randomized, double-blind, split-side, comparison study of moisturizer containing MAS064D and 1% hydrocortisone in the treatment of infantile seborrheic dermatitisseborrheic dermatitischildren less than 1 year oldseborrheic dermatitisMAS064Dƹ% hydrocortisone,efficacy,TCTR20160819001A.Menarini (Thailand) Limited50
进行中（未招募）
Unknown
BE study with clinical endpoint comparing generic bimatoprost ophthalmic solution 0.01% and LUMIGAN® (bimatoprost ophthalmic solution) 0.01% in the treatment of subjects with chronic open-angle glaucoma or ocular hypertension in both eyes.CTRI/2024/02/062212Dr. Ilesh Changela